Table 4 Characteristics of cancer and cancer treatment for all participants (N = 37)

Years since diagnosis (M (SD))

5.8 years (+ / − 6.3 years)

Primary cancer

 Breast

10

 Gastrointestinal

5

 Genitourinary

19

 Lung

2

 Other

1

Type of OAM

 Androgen biosynthesis inhibitor

13

 Androgen receptor inhibitor

4

 Anti-neoplastic/Cytotoxic medication

7

 CDK4/6 Inhibitor

5

 Epidermal growth factor receptor (EGFR inhibitor)

2

 Kinase Inhibitor

3

 Poly adenosine diphosphate-ribose polymerase (PARP) inhibitor

2

 Vascular endothelial growth factor (VGEF) inhibitor

1

 OAM cycle on first assessment in pilot study (Mean (SD))

Cycle 18 (+ / − 12 cycles)

Aim of OAM treatment

 Curative

7

 Palliative

30